Javascript must be enabled to continue!
Figure 6 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
View through CrossRef
<p>Proximity labeling identifies histone acetylase SIRT1 as a direct KDM4C nuclear interactor and a novel KDM4C–SIRT1–DUSP2 axis regulating ERK activity in PDAC. <b>A,</b> Validating biotinylation activity by KDM4C-miniTurboID. AsPC1 cells were transfected with KDM4C-miniTurboID and then treated with 50 μmol/L biotin 24 hours after transfection for 30 minutes. Cells were then lysed and the whole lysates probed for biotin by streptavidin–HRP along with “untransfected” and “KDM4C-miniTurboID without biotin” as controls. <b>B,</b> Cytoscape analysis of the biotinylated nuclear proteins by KDM4C-miniTurboID, with annotated biological processes. <b>C,</b> List of high-confidence nuclear KDM4C interactors based on proximity labeling experiment. The values shown are the abundance ratio between “KDM4C-miniTurboID + biotin” over “KDM4C-miniTurboID without biotin”. <b>D,</b> KDM4C co-immunoprecipitation confirms binding to SIRT1 in PDAC cells but not to PARP1 or ZNF148. IgG isotype antibody was used as a control for nonspecific binding. <b>E,</b> Graphical illustration of KDM4C domain-specific deletion constructs: FL = full-length KDM4C construct, ΔTudor = Tudor domain–deleted KDM4C, ΔPHD = PHD-deleted KDM4C, and ΔJMJ = JMJ domain–deleted KDM4C construct. All constructs are HA-tagged for immunoprecipitation. <b>F,</b> The Tudor domain is responsible for KDM4C binding to SIRT1. HEK293 cells were cotransfected with Flag-tagged SIRT1 construct and either FL KDM4C or a KDM4C domain–deleted construct, and then the cells were lysed, and the HA-enriched eluates for respective samples were probed for SIRT1 using anti-Flag. All constructs could pull down SIRT1 except ΔTudor. <b>G,</b> Venn diagram illustrating high degree of correlation between the genes with increased H3K36me3 and H3K27Ac peaks at the promoter region in <i>KDM4C</i> KO cells. Integrating ChIP-seq with the RNA-seq data results in a list of 16 genes, including the protein phosphatase <i>DUSP2</i>, which targets ERK phosphorylation. <b>H,</b> RT-qPCR of <i>DUSP</i> 1, 2, 4, 5, and 6 in AsPC1 control cells and <i>KDM4C</i> KO shows <i>DUSP2</i> has the highest FC increase in mRNA expression, *, <i>P</i> ≤ 0.05; **, <i>P</i> ≤ 0.01, via unpaired <i>t</i> test. <b>I,</b> Western blot shows increased DUSP2 protein levels in <i>KDM4C</i>-null clones.</p>
American Association for Cancer Research (AACR)
Title: Figure 6 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Description:
<p>Proximity labeling identifies histone acetylase SIRT1 as a direct KDM4C nuclear interactor and a novel KDM4C–SIRT1–DUSP2 axis regulating ERK activity in PDAC.
<b>A,</b> Validating biotinylation activity by KDM4C-miniTurboID.
AsPC1 cells were transfected with KDM4C-miniTurboID and then treated with 50 μmol/L biotin 24 hours after transfection for 30 minutes.
Cells were then lysed and the whole lysates probed for biotin by streptavidin–HRP along with “untransfected” and “KDM4C-miniTurboID without biotin” as controls.
<b>B,</b> Cytoscape analysis of the biotinylated nuclear proteins by KDM4C-miniTurboID, with annotated biological processes.
<b>C,</b> List of high-confidence nuclear KDM4C interactors based on proximity labeling experiment.
The values shown are the abundance ratio between “KDM4C-miniTurboID + biotin” over “KDM4C-miniTurboID without biotin”.
<b>D,</b> KDM4C co-immunoprecipitation confirms binding to SIRT1 in PDAC cells but not to PARP1 or ZNF148.
IgG isotype antibody was used as a control for nonspecific binding.
<b>E,</b> Graphical illustration of KDM4C domain-specific deletion constructs: FL = full-length KDM4C construct, ΔTudor = Tudor domain–deleted KDM4C, ΔPHD = PHD-deleted KDM4C, and ΔJMJ = JMJ domain–deleted KDM4C construct.
All constructs are HA-tagged for immunoprecipitation.
<b>F,</b> The Tudor domain is responsible for KDM4C binding to SIRT1.
HEK293 cells were cotransfected with Flag-tagged SIRT1 construct and either FL KDM4C or a KDM4C domain–deleted construct, and then the cells were lysed, and the HA-enriched eluates for respective samples were probed for SIRT1 using anti-Flag.
All constructs could pull down SIRT1 except ΔTudor.
<b>G,</b> Venn diagram illustrating high degree of correlation between the genes with increased H3K36me3 and H3K27Ac peaks at the promoter region in <i>KDM4C</i> KO cells.
Integrating ChIP-seq with the RNA-seq data results in a list of 16 genes, including the protein phosphatase <i>DUSP2</i>, which targets ERK phosphorylation.
<b>H,</b> RT-qPCR of <i>DUSP</i> 1, 2, 4, 5, and 6 in AsPC1 control cells and <i>KDM4C</i> KO shows <i>DUSP2</i> has the highest FC increase in mRNA expression, *, <i>P</i> ≤ 0.
05; **, <i>P</i> ≤ 0.
01, via unpaired <i>t</i> test.
<b>I,</b> Western blot shows increased DUSP2 protein levels in <i>KDM4C</i>-null clones.
</p>.
Related Results
Abstract C081: The lysine demethylase KDM4C is an oncogenic driver in pancreatic ductal adenocarcinoma
Abstract C081: The lysine demethylase KDM4C is an oncogenic driver in pancreatic ductal adenocarcinoma
Abstract
Deregulation of proteins involved in chromatin regulation is common in pancreatic ductal adenocarcinoma (PDAC), occurring via both genomic and non-genomic m...
Data from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Data from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
<div>Abstract<p>Deregulation of proteins involved in chromatin regulation is common in pancreatic ductal adenocarcinoma (PDAC). Lysine demethylase 4C (KDM4C) is one of ...
Figure 4 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Figure 4 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
<p>Compensatory upregulation of KDM4A restores cell-intrinsic ERK signaling in <i>KDM4C</i>-null cells but not immune surveillance. <b>A,</b> Western ...
Figure 2 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Figure 2 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
<p>CRISPR-mediated <i>KDM4C</i> deletion attenuates PDAC growth <i>in vitro</i> and <i>in vivo</i>. <b>A,</b> Western blot sho...
Figure 1 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Figure 1 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
<p>KDM4C is differentially upregulated in pancreatic cancer and correlates with poor prognosis. <b>A,</b> Western blots show human PDAC cell lines overexpress KDM...
Abstract 5735: Novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose-dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D-mutated cancer models
Abstract 5735: Novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose-dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D-mutated cancer models
Abstract
KRAS is one of the most frequently mutated oncogenes in various cancers. Among KRAS mutations, KRAS G12D is the most frequent driver mutation and is found i...
Kras Plays An Important Role In Generating Differentiated Blood Cells
Kras Plays An Important Role In Generating Differentiated Blood Cells
Abstract
Background
Kras is a small GTPase essential for mouse embryonic development. Although Kras-/- fetal liver cells reconst...
The molecular mechanism underlying KRAS regulation on STK31 expression in Pancreatic ductal adenocarcinoma
The molecular mechanism underlying KRAS regulation on STK31 expression in Pancreatic ductal adenocarcinoma
Abstract
KRAS mutations are common in pancreatic ductal adenocarcinoma (PDAC) but targeting mutant KRAS is still challenging. Kinase inhibitors are ideal targeted therapeut...

